NASDAQ: HELPCybin Inc Stock
$7.44-0.29 (-3.75%)
Updated Jan 6, 2026
HELP Price
$7.44
Fair Value Price
$0.73
Market Cap
$171.37M
52 Week Low
$4.81
52 Week High
$10.72
P/E
-2.33x
P/B
1.73x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$72.07M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.3
Operating Cash Flow
-$81M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HELP Overview
Cybin Inc. is a biotechnology company focused on researching and progressing psychedelic therapeutics for psychiatric disorders. It has also developed EMBARK, psychedelic-assisted psychotherapy. The company's development pipeline includes CYB003, CYB004, and CYB005, among others. The company was founded in 2019 and is headquartered in Toronto, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HELP's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
HELP
Ranked#471 of 494
Ranked#471 of 494
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $16.86 | A | |
| $15.44 | A | |
| $6.40 | A |
Be the first to know about important HELP news, forecast changes, insider trades & much more!
HELP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HELP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HELP ($7.44) is overvalued by 921.75% relative to our estimate of its Fair Value price of $0.73 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HELP ($7.44) is not significantly undervalued (921.75%) relative to our estimate of its Fair Value price of $0.73 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HELP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HELP due diligence checks available for Premium users.
Valuation
HELP fair value
Fair Value of HELP stock based on Discounted Cash Flow (DCF)
Price
$7.44
Fair Value
$0.73
Overvalued by
921.75%
HELP ($7.44) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HELP ($7.44) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HELP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HELP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.33x
Industry
156.09x
Market
44.15x
HELP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.73x
Industry
5.36x
HELP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HELP's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.4M
Profit Margin
0%
HELP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$131.3M
Liabilities
$30.6M
Debt to equity
0.3
HELP's short-term assets ($81.84M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HELP's short-term assets ($81.84M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HELP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$25.0M
Investing
-$315.9k
Financing
$19.6k
HELP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HELP vs Biotech Stocks
Cybin Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.